HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in...
Hence then, the article about first patient dosed in phase iii perioperative study of cadonilimab pd 1 ctla 4 in colon cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer )
Also on site :
- ‘Triangle of Sadness’ Producer Backs Park Syeyoung’s Memory-Bending Love Motel Drama ‘Satellite of Love’ at Busan Asian Project Market
- Taylor Swift Shows Up on ‘Law & Order: SVU’ Set With a Surprise—and Mariska Hargitay Can’t Stop Talking About It
- ’80s Rock Band With Six Lead Singers Is Approaching Its Farewell Tour—and Fans Have a Major Date to Know